An anti-cocaine vaccine (e.g. TA-CD) is one of several novel approaches utilizing an immunological mechanism of action for the treatment of SUDs. TA-CD, composed of a cocaine hapten conjugated to inactivated cholera toxin B, increases production of antibodies that target the cocaine molecule. The antibodies bind to cocaine in the blood and, because the antigen–antibody complexes are too large to cross the blood–brain barrier, prevent cocaine from entering the brain [107,108]. Both crack cocaine and cocaine can be extremely dangerous, whether used once or more frequently.
Because cocaine is a highly addictive substance, it can cause dependence ― which is where your body becomes dependent on the drug and needs more of it to have the same effects. Cocaine dependence https://ecosoberhouse.com/article/the-6-stages-of-alcoholic-recovery-timeline/ can also cause withdrawal symptoms when attempting to stop or detox from the drug. Since many people abuse cocaine at parties or social events, they may not know they are addicted.
Behavioral Interventions
To achieve the latter, a combination approach may be beneficial, such as targeting drug withdrawal and cravings and allowing patients to benefit more from behavioural/psychosocial interventions [20]. Studies have identified positive cocaine addiction treatment signals for a range of medications for treating CUD. These include long-acting amphetamine formulations, modafinil, topiramate, doxazosin and combined topiramate and mixed amphetamine salts extended-release (MAS-ER).
- To make cocaine, the leaves are chemically processed and treated to form a powder.
- Overall, the mixed results of modafinil trials to date do not suggest significant efficacy of this drug in cocaine users as a whole.
- Because this was a proof-of-concept trial, the investigators applied stringent retention criteria, requiring participants to provide at least 75% of the requested data for any 2-week period of the trial.
The new law rolls back a 2020 voter-approved measure by making so-called personal use possession a misdemeanor punishable by up to six months in jail. It also establishes ways for treatment to be offered as an alternative to criminal penalties by encouraging law enforcement agencies to create deflection programs that would divert people to addiction and mental health services instead of the criminal justice system. Call the rehab center of your choice and ask if they offer men-only or women-only addiction treatment programs. People with alcohol or opioid addiction can access medication-assisted treatment (MAT), which involves medications to reduce cravings and minimize withdrawal symptoms. The Recovery Village is an inpatient rehab center in Colorado that provides opioid, alcohol, amphetamine, and benzodiazepine addiction treatment.
Drug Trade Name Key
For that reason, it is often best to seek treatment at a facility that offers gender-specific programs. Oftentimes, the drug that an individual is addicted to will influence what kind of treatment they need for their recovery journey. Because each drug is different and each person has different needs, it is important to find the program that will work best for you. These low or no-cost treatment centers are funded by the government or through donations. When looking for a treatment program, be sure to find one that offers not only a high treatment retention rate, but also other marks of quality care.
Almost all who seek treatment for CUD receive psychosocial interventions, but most will continue to use cocaine [14]. Pharmacotherapies may augment the effectiveness of psychosocial interventions, but no Food and Drug Administration (FDA)-approved medications for treating CUD are currently available. Challenges confronting the development of psychosocial treatments for CUD lie less in identifying more effective strategies but more on finding innovative ways of applying these strategies.
Medical Innovator: Farah Sheikh
Some of the differences in trial outcome may be explained by comorbid alcohol abuse among some of the subjects. Some of the differences may also be explained by the severity of CUD in the sample being tested or by varying adherence to modafinil treatment. In most, but not all, trials of long-acting amphetamine or methamphetamine treatment, retention has been poor. In at least one trial, the poor retention rate was due, not to poor tolerability of the medication, but rather to the stringent retention criteria used in these preliminary proof-of-concept trials.